A new trading day began on August 04, 2022, with Apellis Pharmaceuticals Inc. (NASDAQ: APLS) stock priced at $58.05, up 5.96% from the previous day of trading. During the day, the shares moved up to $62.37 and dropped to $58.03 before settling in for the closing price of $57.88. APLS’s price has ranged from $27.50 to $67.74 over the past 52 weeks.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Meanwhile, its annual earnings per share averaged -92.70%. With a float of $88.35 million, this company’s outstanding shares have now reached $98.07 million.
Let’s look at the performance matrix of the company that is accounted for 476 employees. In terms of profitability, gross margin is +97.46, operating margin of -805.67, and the pretax margin is -1120.75.
Apellis Pharmaceuticals Inc. (APLS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc. is 2.60%, while institutional ownership is 90.20%. The most recent insider transaction that took place on Aug 03, was worth 282,150. In this transaction Chief Commercial Officer of this company sold 5,000 shares at a rate of $56.43, taking the stock ownership to the 37,907 shares. Before that another transaction happened on Aug 01, when Company’s CHIEF MEDICAL OFFICER sold 2,500 for $55.99, making the entire transaction worth $139,975. This insider now owns 107,384 shares in total.
Apellis Pharmaceuticals Inc. (APLS) Latest Financial update
In its latest quarterly report, released on 3/30/2022, the company reported earnings of -$1.42 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of -1121.27 while generating a return on equity of -370.20. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -92.70% per share during the next fiscal year.
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Trading Performance Indicators
Here are Apellis Pharmaceuticals Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 82.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.02, a number that is poised to hit -1.36 in the next quarter and is forecasted to reach -4.40 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc. (APLS)
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) saw its 5-day average volume 1.03 million, a negative change from its year-to-date volume of 1.1 million. As of the previous 9 days, the stock’s Stochastic %D was 81.89%. Additionally, its Average True Range was 3.00.
During the past 100 days, Apellis Pharmaceuticals Inc.’s (APLS) raw stochastic average was set at 96.42%, which indicates a significant increase from 94.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.82% in the past 14 days, which was higher than the 64.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.20, while its 200-day Moving Average is $44.59. Nevertheless, the first resistance level for the watch stands at $63.12 in the near term. At $64.92, the stock is likely to face the second major resistance level. The third major resistance level sits at $67.46. If the price goes on to break the first support level at $58.78, it is likely to go to the next support level at $56.24. The third support level lies at $54.44 if the price breaches the second support level.
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Key Stats
With a market capitalization of 6.66 billion, the company has a total of 106,522K Shares Outstanding. Currently, annual sales are 66,560 K while annual income is -746,350 K. The company’s previous quarter sales were 14,380 K while its latest quarter income was -138,940 K.